Ohr Pharmaceutical Inc (NASDAQ:OHRP) 2018 Q2 Sentiment Change, Now at 0.67

OHR Pharmaceutical, Inc. (NASDAQ:OHRP) Corporate Logo

Positions for Ohr Pharmaceutical Inc (NASDAQ:OHRP)

“Big money sentiment for Ohr Pharmaceutical Inc (NASDAQ:OHRP) in 2018 Q2 decreased to 0.67, SEC filings reveal. That’s down -0.15, from 2018Q1’s 0.82. 6 active investment managers increased and opened new stock positions, while 9 cut down and sold their stock positions in Ohr Pharmaceutical Inc so the sentiment has worsened. These funds own 5.00 million shares, that’s down from 5.09 million shares in 2018Q1. Funds holding Ohr Pharmaceutical Inc in top 10 changed to 0 from 0 for the same number . In total 4 funds closed positions, 5 reduced and 4 increased. Also 2 funds bought new Ohr Pharmaceutical Inc stakes.

Most Ohr Pharmaceutical Inc Shareholders

As of 2018 Q2 Garrison Bradford & Associates Inc has 0.07% invested in Ohr Pharmaceutical Inc. As of 2018 Q2, 500 shares of Ohr Pharmaceutical Inc are owned by Bank Of America Corp De. Bank Of New York Mellon Corp reported 34,472 shares. The New York-based fund Blackrock Inc. have invested about 0% of the investment manager’s stock portfolio in Ohr Pharmaceutical Inc. The Pennsylvania-based fund Bryn Mawr Trust Co looks positive on Ohr Pharmaceutical Inc, owning 10,000 shares.

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease.The company has $7.91 million market cap. The Company’s lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.Currently it has negative earnings. The firm is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion.

Ticker’s shares touched $0.14 during the last trading session after 4.32% change.Currently OHR Pharmaceutical, Inc. is downtrending after 74.70% change in last December 8, 2017. OHRP has 647,349 shares volume. OHRP underperformed by 90.32% the S&P 500.

New York-based Blackrock has invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Susquehanna International Grp Llp has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). California Employees Retirement reported 0% of its capital in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Finemark Natl National Bank & Trust invested 0% in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). State Street invested in 10,400 shs or 0% of the stock. Moreover, Natl Bank Of America De has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP). Wells Fargo Mn owns 167 shs. Janney Montgomery Scott Ltd Liability invested in 10,500 shs or 0% of the stock. Renaissance Limited Liability Corp has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 1.14 million shs. First Manhattan Company reported 7,215 shs. Moreover, Two Sigma Secs has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 56,697 shs. 268,161 were accumulated by Geode Cap Ltd Liability Corp. Bryn Mawr Tru has 0% invested in OHR Pharmaceutical, Inc. (NASDAQ:OHRP) for 10,000 shs. Citadel Advsr Ltd Liability invested in 68,964 shs. Grp Inc One Trading L P owns 54,303 shs.

For more OHR Pharmaceutical, Inc. (NASDAQ:OHRP) news released recently go to: Seekingalpha.com, Benzinga.com, Benzinga.com, Businesswire.com or Seekingalpha.com. The titles are as follows: “Ohr Pharma’s MAKO study fails – Seeking Alpha” released on January 05, 2018, “Biggest Biotech Catalysts Coming In The Second Half Of 2018 (NASDAQ:IBB) – Benzinga” on July 05, 2018, “Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos’ Maiden Earnings, Paratek Awaits Adcom Verdict – Benzinga” with a publish date: August 08, 2018, “Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action – Business Wire” and the last “Phase II Calamity Dooms Ohr’s Eye Drops – Seeking Alpha” with publication date: June 28, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.